

Comparative analysis of the outcomes of COVID-19 between patients infected with SARS-CoV-2 Omicron and Delta variants: a retrospective cohort study

Gunadi^{1*}, Mohamad Saifudin Hakim², Hendra Wibawa³, Khanza Adzkia Vujira⁴, Dyah Ayu Puspitarani⁵, Endah Supriyati⁶, Ika Trisnawati⁷, Kristy Iskandar⁸, Riat El Khair⁹, Afiahayati¹⁰, Siswanto¹¹, Yunika Puspawati¹², Irene¹³, Sri Handayani Irianingsih¹⁴, Edwin Widyanto Daniwijaya¹⁵, Dwi Aris Agung Nugrahaningsih¹⁶, Gita Christy Gabriela¹⁷, Esensi Tarian Geometri¹⁸, Laudria Stella Eryvinka¹⁹, Fadila Dyah Trie Utami²⁰, Edita Mayda Devana²¹, Lanang Aditama²², Nathania Christi Putri Kinasih²³, Verrell Christopher Amadeus²⁴, Yekti Hediningsih²⁵, Nur Rahmi Ananda²⁶, Eggi Arguni²⁷, Titik Nuryastuti²⁸, Tri Wibawa²⁹, on behalf of the Yogyakarta-Central Java COVID-19 study group

¹Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; drgunadi@ugm.ac.id

²Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; m.s.hakim@ugm.ac.id

³Disease Investigation Center Wates (Balai Besar Veteriner Wates), Yogyakarta, Directorate General, and Livestock Services, Ministry of Agriculture Indonesia; hendra.wibawa@pertanian.go.id

⁴Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; khanza.adzkia.v@mail.ugm.ac.id

⁵Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; raden.ajeng.d@mail.ugm.ac.id

⁶Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; endah.supriyati@worldmosquito.org

⁷Pulmonology Division, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia; ika.interna@gmail.com

⁸Department of Child Health/Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/UGM Academic Hospital, Yogyakarta, Indonesia; kristy.iskandar@ugm.ac.id

⁹Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, 55281, Indonesia; dr.riat@yahoo.co.id

¹⁰Department of Computer Science and Electronics Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia; afia@ugm.ac.id

¹¹Department of Physiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/UGM Academic Hospital, Yogyakarta, Indonesia; sis12@ugm.ac.id

¹²Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, 55281, Indonesia; yunika_puspadewi@yahoo.com

¹³Balai Besar Teknik Kesehatan Lingkungan dan Pengendalian Penyakit, Yogyakarta, Yogyakarta, Indonesia; irenepunya@gmail.com

¹⁴Disease Investigation Center Wates (Balai Besar Veteriner Wates), Yogyakarta, Directorate General, and Livestock Services, Ministry of Agriculture Indonesia; shirianingsih@gmail.com

¹⁵Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/UGM Academic Hospital, Yogyakarta, Indonesia; m.edwin.d@ugm.ac.id

¹⁶Department of Pharmacology and Therapy/Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; dwi.aris.a@ugm.ac.id

¹⁷Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; gabriela_christy@ymail.com

¹⁸Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; esensi.tarian.g@mail.ugm.ac.id

¹⁹Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; laudriastella@mail.ugm.ac.id

²⁰Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; fadila.d@mail.ugm.ac.id

²¹Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; devaribi@gmail.com

²²Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; lanang.aditama@gmail.com

²³Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; nathania.c@mail.ugm.ac.id

²⁴Pediatric Surgery Division, Department of Surgery/Genetics Working Group/Translational Research Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; verrellc@gmail.com

²⁵Balai Laboratorium Kesehatan dan Pengujian Alat Kesehatan, Centra Java, Indonesia; yektipatklin@gmail.com

²⁶Pulmonology Division, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia; nur.rahmi@mail.ugm.ac.id

²⁷Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia; eggiarguni@ugm.ac.id

²⁸Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; t.nuryastuti@ugm.ac.id

²⁹Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; twibawa@ugm.ac.id

Running title: Omicron and Delta variants outcomes

***Address all correspondence to:**

Gunadi, MD, Ph.D.

Genetics Working Group/Translational Research Unit

Pediatric Surgery Division, Department of Surgery

Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital

Jl. Kesehatan No. 1 Yogyakarta 55281, Indonesia

drgunadi@ugm.ac.id

Abstract

Background: The SARS-CoV-2 Omicron variant has replaced the previously dominant Delta variant because of high transmissibility. It is responsible for the current increase in the COVID-19 infectivity rate worldwide. However, studies on the impact of the Omicron variant on the severity of COVID-19 are still limited in developing countries. Here, we compared the outcomes of patients infected with SARS-CoV-2 Omicron and Delta variants and associated with prognostic factors, including age, sex, comorbidities, and smoking.

Methods: We involved 352 patients, 139 with the Omicron variant and 213 with the Delta variant. The whole-genome sequences of SARS-CoV-2 were conducted using the Illumina MiSeq next-generation sequencer.

Results: Ct value and mean age of COVID-19 patients were not significantly different between both groups (Delta: 20.35 ± 4.07 vs. Omicron: 20.62 ± 3.75 ; $p=0.540$; and Delta: 36.52 ± 21.24 vs. Omicron: 39.10 ± 21.24 ; $p=0.266$, respectively). Patients infected with Omicron and Delta variants showed similar hospitalization ($p=0.433$) and mortality rates ($p=0.565$). Multivariate analysis showed that older age (≥ 65 years) had higher risk for hospitalization (OR=3.67 [95% CI=1.22-10.94]; $p=0.019$) and fatalities (OR=3.93 [95% CI=1.35-11.42]; $p=0.012$). In addition, patients with cardiovascular disease had higher risk for hospitalization (OR=5.27 [95% CI=1.07-25.97]; $p=0.041$), whereas patients with diabetes revealed higher risk for fatalities (OR=9.39 [95% CI=3.30-26.72]; $p<0.001$).

Conclusions: Our study shows that patients infected with Omicron and Delta variants reveal similar clinical outcomes, including hospitalization and mortality. In addition, our findings further confirm that older age, cardiovascular disease, and diabetes are strong prognostic factors for the outcomes of COVID-19 patients.

Keywords: Delta variant; hospitalization; mortality; Omicron variant; SARS-CoV-2; COVID-19 outcomes; whole-genome sequencing

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing global pandemic of Coronavirus disease 2019 (COVID-19). As RNA viruses, SARS-CoV-2 is undergoing continuous mutation and evolution, giving rise to novel variants with the selective fitness advantage [1]. These variants have different characteristics due to their unique sets of mutations, including transmission rate, immune escape, and clinical severity. Variants with sufficient evidence of increased transmissibility, more severe diseases, or reduced vaccine or antiviral drug effectiveness have been designated a variant of concern (VOC). Therefore, these variants continuously impact both global health and the economy, with millions of people infected, hospitalized, and dead [2,3].

The Omicron variant (B.1.1.529) was first identified in a sample collected in Botswana on November 11, 2021. However, it was first reported by South Africa on November 24, 2021. Only within two days, the Omicron was classified as a variant of concern (VOC) by the World Health Organization on November 26, 2021 [4,5]. In Indonesia, the surge of COVID-19 cases due to the Omicron variant occurred from late January until February 2022. Subsequently, the Omicron variant was found as the most frequently detected VOC compared to the previously dominating Delta variant [6]. SARS-CoV-2 genomic surveillance in Indonesia is continuously conducted to monitor circulating SARS-CoV-2 variants.

Because of high transmissibility, the SARS-CoV-2 Omicron variant has replaced the previous dominant variant, i.e., the Delta variant. It was responsible for the current increase in the COVID-19 infectivity rate worldwide, including in Indonesia [7-9]. However, studies on the impact of the Omicron variant on the clinical severity of COVID-19 are still limited in developed countries [10-12]. Several studies in developed countries showed a lower clinical severity of

Omicron-infected patients than Delta-infected patients [10-12]. Several factors have been associated with the clinical severity of infection, including vaccination status and the previous SARS-CoV-2 infection. In addition, we and others have shown that several prognostic factors have been associated with the outcomes of COVID-19 [13-17]. Therefore, to further comprehend the impact of the Omicron wave in developing countries, we performed a comparative analysis of the outcomes of COVID-19 patients infected with Delta and Omicron variants and associated them with several prognostic factors, including age, sex, comorbidities, and smoking. Our study thus contributes to informing the public health response against the emerging SARS-CoV-2 variants.

Material and Methods

Subjects

We used data from 352 patients with COVID-19 from Yogyakarta and Central Java provinces, Indonesia, from May 2021 to February 2022, consisting of 164 males and 188 females. The diagnosis of COVID-19 was defined according to PCR results for SARS-CoV-2. We included all patients with the PCR's Ct value of less than 30 for further whole-genome sequencing. Outcomes of patients with COVID-19 were hospitalization and mortality. The Medical and Health Research Ethics Committee of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, approved our study (KE/FK/0563/EC/2020).

Whole-genome sequencing of SARS-CoV-2

We collected all samples from nasopharyngeal swabs of outpatient or hospitalized patients with COVID-19 from May 2021 to February 2022. Subsequently, samples were sent to COVID-19

Testing Laboratory Network in Yogyakarta for PCR and to Balai Besar Veteriner Wates and Balai Besar Teknik Kesehatan Lingkungan dan Pengendalian Penyakit Yogyakarta for whole-genome sequencing using MiSeq Illumina Platform.

We conducted whole-genome sequencing (WGS) of SARS-CoV-2 for all samples with PCR's Ct value of less than 30. As described in our previous studies [13,14,18,119], single-stranded cDNA was synthesized from total RNA extracted from the samples of COVID-19 patients by SuperScript™ III First-Strand Synthesis System (Thermo Fisher Scientific, MA, United States). Subsequently, the second strand was synthesized by COVID-19 ARTIC v3 primer pool design by SARS-CoV-2 ARTIC Network using Phusion™ High-Fidelity DNA Polymerase (Thermo Fisher Scientific, MA, United States). The library preparations were performed using the Illumina DNA Prep (Illumina, California, United States). The Illumina MiSeq next-generation sequencer was used to perform the whole genome sequences of SARS-CoV-2. The genomes of our samples were assembled and mapped into the reference genome from Wuhan, China (hCoV-19/Wuhan/Hu-1/2019, GenBank accession number: NC_045512.2) using Burrow-Wheeler Aligner (BWA) algorithm embedded in UGENE v. 1.30 [20].

Phylogenetic study

A dataset of 392 available SARS-CoV-2 genomes was extracted from GISAID from our region and others (Acknowledgment Table is provided in Supp. Table 1) to reconstruct the phylogenetic tree. This included SARS-CoV-2 genomes from 352 virus samples collected from our study in Central Java and Yogyakarta Special Regions provinces during Delta and Omicron variant infection waves in 2021 and 2022 and 40 virus genomes of other SARS-CoV-2 variants that previously circulated in Indonesia (B.1.1.7/Alpha, B.1.466.2, B.36, and B.1.470). Firstly, a

multiple nucleotide sequence alignment was performed using the MAFFT program version 7 (<https://mafft.cbrc.jp/alignment/server/>). The neighbor-joining statistical method with 1,000 bootstrap replications [21,22] was used to construct a phylogenetic tree from 29,409 nucleotide length of the open reading frame (ORF) of SARS-CoV-2, followed by computation of the evolutionary distances and model of the rate variation among sites by the Kimura 2-parameter method and the gamma distribution with estimated shape parameter (α) for the dataset, respectively [23]. The DAMBE version 7 [24] was utilized to calculate the estimation of the α gamma distribution, MEGA version 10 (MEGA X) [25] for phylogenetic reconstruction, and followed by tree visualization in FigTree (<http://tree.bio.ed.ac.uk/software/figtree/>) to using a Newick tree output from MEGA X.

Prognostic variables

We associated the outcomes of COVID-19 patients with the following prognostic variables: sex; age; comorbidities, including obesity, diabetes, hypertension, cardiovascular disease, and chronic kidney disease; and smoking. According to the previous reports, those prognostic factors were selected [13-17].

Statistical analysis

The data were presented as mean \pm SD and frequency (percentage). We determined the normality of the continuous variables by the Kolmogorov-Smirnov test. We excluded the missing or incomplete data from the final analysis. We used Chi-square or Fisher exact tests with a 95% confidence interval (CI) to find any significant association between variables and the outcomes of COVID-19 patients. Subsequently, we performed a multivariate analysis using a

logistic regression test. We considered the p -value of <0.05 as significant. We conducted all statistical analyses by the IBM Statistical Package for the Social Sciences (SPSS) version 23 (Chicago, USA).

Results

Phylogenetic study

Phylogenetic analysis showed that about 60.5% (213 samples) of SARS-CoV-2 collected from Central Java and Yogyakarta provinces between May 2021 and February 2022 belonged to B.1.617.2-like (Delta variant), while 39.5% (139 samples) clustered in BA-like (Omicron variant) (Fig.1). The majority of Delta variants were AY.23 lineage (91.5%), whereas a small proportion was AY.24 lineage (8.5%). For the Omicron variant, BA.1 lineage was predominantly detected (77.7%), followed by BA.2 lineage (21.6%), and only one virus (0.7%) belonged to BA.3 lineage (hcov-19/Indonesia/YO-GS-22.02175/2022: EPI_ISL_9702414). In particular, to BA.1-like virus, SARS-CoV-2 viruses from Central Java and Yogyakarta that belonged to this lineage breached into three distinct groups consisting of BA.1.13, BA.1.14, BA.1.15 (Group I), BA.1.1, BA.1.17, BA.1.18 (Group II), and a unique cluster of BA.1.13 (Group III) (Figure 1).

Clinical characteristics of our patients

Ct value and mean age were not significantly different between both groups (Delta: 20.35 ± 4.07 vs. Omicron: 20.62 ± 3.75 ; $p=0.540$; and Delta: 36.52 ± 21.24 vs. Omicron: 39.10 ± 21.24 ; $p=0.266$, respectively) (Table 1). All clinical characteristics of both groups were similar, except for the comorbidities of diabetes ($p=0.022$) and chronic kidney disease ($p=0.019$) (Table 1).

Table 1. Clinical characteristics of COVID-19 patients involved in this study.

Characteristics	Total (N=352)	Delta (N=213)	Omicron (N=139)	p-value
	N (%); mean \pm SD	N (%); mean \pm SD	N (%); mean \pm SD	
Ct value	20.46 \pm 3.95	20.35 \pm 4.07	20.62 \pm 3.75	0.540
Age (years)	37.54 \pm 21.25	36.52 \pm 21.24	39.10 \pm 21.24	0.266
☐ \geq 65	37 (10.5)	53 (24.9)	28 (20.3)	
☐ 18 - <65	234 (66.5)	140 (65.7)	94 (68.1)	
☐ <18	81 (23)	20 (9.4)	17 (11.6)	
Sex				0.072
☐ Male	164 (46.6)	91 (42.7)	73 (52.5)	
☐ Female	188 (53.4)	122 (57.2)	66 (47.5)	
Comorbidities				
☐ Obesity	4 (1.1)	4 (1.9)	0	0.149
☐ Diabetes	29 (8.2)	23 (10.8)	6 (4.3)	0.022*
☐ Hypertension	36 (10.7)	25 (11.7)	12 (8.6)	0.425
☐ Cardiovascular disease	23 (6.9)	12 (5.6)	11 (7.9)	0.464
☐ Chronic kidney disease	7 (2.1)	1 (0.5)	6 (4.3)	0.019*
Smoking	17 (5.1)	12 (5.6)	5 (3.6)	0.335

*, $p < 0.05$

Prognostic factors for outcomes of patients with COVID-19

The hospitalization and mortality rates were not significantly different between patients infected with Omicron and Delta variants (Table 2). The older patients were less hospitalized than the

younger subjects ($p < 0.000$), but they had a higher risk for mortality than younger ones (OR=6.91 [95%CI=2.84-16.86]; $p < 0.000$). Patients with diabetes, hypertension, cardiovascular disease, and chronic kidney disease showed a higher hospitalization risk. In addition, subjects with obesity, diabetes, hypertension, cardiovascular disease, and smoking revealed a higher risk for fatalities (Table 2).

Table 2. Prognostic factors for outcomes of COVID-19 patients

Variables	Hospitalized (N, %)	p-value	OR (95% CI)	Mortality (N, %)	p-value	OR (95% CI)
SARS-CoV-2 variant						
☐ Delta (N=213)	111 (52.1)	0.396	0.83 (0.54-1.27)	19 (8.9)	0.566	0.79 (0.36-1.76)
☐ Omicron (N=139)	66 (47.8)			10 (7.2)		
Age						
☐ <65-18 (N=234)	124 (53.2)	Ref		14 (6)	Ref	
☐ ≥65 (N=36)	5 (13.9)	<0.000*	0.14 (0.05-0.38)	11 (30.6)	<0.000*	6.91 (2.84-16.86)
☐ <18 (N=82)	37 (54.3)	0.221	0.73 (0.44-1.2)	4 (4.9)	0.791	0.81 (0.26-2.52)
Sex						
☐ Female (N=188)	96 (51.3)	0.754	0.94 (0.62-1.42)	13 (6.9)	0.332	0.69 (0.32-1.48)
☐ Male (N=164)	81 (49.4)			16 (9.8)		
Comorbidity						
a. Obesity						
Yes (N=4)	4 (100)	0.123	9.10 (0.49-170.38)	2 (50)	0.035*	11.90 (1.61-87.76)
No (N=348)	173 (49.9)			27 (7.8)		
b. Diabetes						
Yes (N=29)	29 (100)	<0.000*	69.73 (4.22-1150.98)	13 (44.8)	<0.000*	15.59(6.42-37.88)
No (N=323)	148 (46)			16 (5)		
c. Hypertension						
Yes (N=37)	29 (80)	<0.000*	4.09 (1.81-9.92)	11 (31.4)	<0.000*	7.28 (3.10-17.11)
No (N=315)	149 (47.2)			18 (5.7)		

d. Cardiovascular disease						
Yes (N=23)	21 (91.3)	<0.000*	11.64 (2.69-50.47)	7 (30.4)	0.001*	6.11 (2.27-16.40)
No (N=329)	156 (47.6)			22 (6.7)		
e. Chronic kidney disease						
Yes (N=7)	7 (100)	0.015*	2.02 (1.81-2.25)	1 (14.3)	0.56	1.89 (0.22-16.23)
No (N=345)	170 (49.4)			28 (8.1)		
Smoking						
☐ Yes (N=17)	9 (52.9)	0.823	1.12 (0.42-2.97)	4 (23.5)	0.042*	3.82 (1.16-12.57)
☐ No (N=335)	168 (50.3)			25 (7.5)		

*, significant ($p < 0.05$); CI, confidence interval; OR, odds ratio

Multivariate analysis of prognostic factors

Subsequently, we conducted a multivariate analysis to determine the independent prognostic factors for the hospitalization and mortality of patients with COVID-19. The analysis revealed that older age (>65 years) had higher risk to be hospitalized (OR=3.67 [95% CI=1.23-10.94]; $p=0.019$) and died (OR=3.93 [95% CI=1.35-11.42]; $p=0.012$). In addition, patients with cardiovascular disease had higher risk to be hospitalized (OR=5.27 [95% CI=1.07-25.97]; $p=0.041$), whereas patients with diabetes revealed higher risk to be died (OR=9.39 [95% CI=3.30-26.72]; $p < 0.001$) (Table 3).

Table 3. Multivariate analysis of prognostic factors for outcomes of patients with COVID-19.

Variables	Hospitalized		Mortality	
	OR (95% CI)	<i>p</i>-value	OR (95% CI)	<i>p</i>-value
Omicron	0.83 (0.52-1.34)	0.456	1.15 (0.45-2.98)	0.768
Age (≥ 65 years)	3.67 (1.23-10.94)	0.019*	3.93 (1.35-11.42)	0.012*

Sex (Male)	1.10 (0.43-2.81)	0.839	0.91 (0.57-1.48)	0.731
Comorbidity				
☐ Obesity	-	0.998	3.61 (0.32-40.64)	0.299
☐ Diabetes	-	0.999	9.39 (3.30-26.72)	<0.001*
☐ Hypertension	2.08 (0.73-5.93)	0.172	2.26 (0.75-6.74)	0.146
☐ Cardiovascular disease	5.27 (1.07-25.97)	0.041*	1.68 (0.45-6.28)	0.438
☐ Chronic kidney disease	-	0.999	1.39 (0.09-21.72)	0.811
Smoking	0.56 (0.16-1.97)	0.364	2.06 (0.39-10.77)	0.393

*, significant ($p < 0.05$); CI, confidence interval; OR, odds ratio; -, not applicable

Discussion

Here, we show that the outcomes of patients infected with the Omicron variant are similar to patients infected with Delta variant regarding the hospitalization and mortality rates. Our findings were different from previous reports [10-12]. Nyberg *et al.* demonstrated that the outcomes of Omicron were significantly less severe than Delta and varied among ages [10]. Lewnard *et al.* showed that Omicron-infected patients had a lower risk of hospitalization, admission to the intensive care unit (ICU), use of ventilation, and death than Delta-infected patients. The differences were more significant in unvaccinated COVID-19 patients [11]. Importantly, Bouzid *et al.* indicated that Omicron patients had higher COVID-19 vaccination coverage [12]. Differences between our findings and previous reports might be affected by several variables, including host genetic background, public health measures, previous SARS-CoV-2 infections, and vaccination coverage [26-31,]. Unfortunately, incomplete data on

vaccination status and previous SARS-CoV-2 infections of our patients hampered us to analyze further the impact of both variables on hospitalization and mortality in our patient cohort. Up to April 16, 2022, the vaccination coverage in Indonesia was 95.13% and 78.08% of the population for single and double doses, respectively [32]. In addition, the outcome of COVID-19 varies among the ethnic group [26-28]. Therefore, further study is essential to determine the association between host genetic risk alleles and the COVID-19 outcomes in our patients. Notably, while a previous study only analyzed patients admitted to the emergency department [12], we comprehensively analyzed the patients both in the hospital and community.

Previous studies showed that older age and comorbidities are significant prognostic factors for hospitalization and mortality [13-15,33,34]. Our study further provides evidence that older age, diabetes, and cardiovascular diseases as strong prognostic factors for the outcomes of COVID-19 patients. A recent systematic review showed that 50%, 20%, and 10% of older patients with COVID-19 had a severe illness, critical illness and died, respectively [35]. Several variables had attributed to the worse outcomes of COVID-19 in older patients, including associated comorbidities and delayed diagnosis due to atypical clinical manifestations [35]. Eighty percent of older patients with COVID-19 had a minimum of one comorbidity, such as hypertension, diabetes, and cardiovascular diseases [35]. Diabetes patients might have an uncontrolled immune response and increased ACE-2 receptors and furin during SARS-CoV-2 infection, while the use of antihypertension causes aberrant ACE-2 receptor expression in hypertension patients [36]. Both mechanisms lead to the severe illness of COVID-19 patients [36]. A recent report revealed that COVID-19 patients showed a higher risk of having cardiovascular diseases one month after acute infection [37]. They strongly suggest that the

survival patients should be closely followed-up for the cardiovascular diseases after acute COVID-19 infection [37].

Children were more hospitalized during the Omicron surge than another variant surge [38]. The risk of hospitalization in children under four years during the Omicron surge was 5-times higher than during the Delta surge, particularly infants <6 months old [39]. However, the COVID-19 severity was not affected by age [39]. It is suggested to vaccinate any eligible subjects, including pregnant woman, family members, and their caregivers, to prevent children <4 years from getting COVID-19 infection [39]. Interestingly, maternal antibodies developed following vaccination can undergo transplacental transfer. Indeed, younger children can receive protection [39]. Our study did not show any difference in hospitalization and mortality rates between children and adults. Moreover, we grouped all pediatric populations from neonates, infants, young and older children into one group, i.e., <18 years.

A previous study showed that the Ct value of Omicron was significantly higher than Delta, implying that higher transmission of Omicron does not necessarily associate with its viral load [40]. Their findings might be affected by the vaccination and prior infection of COVID-19 due to the vaccination coverage and infection rate being higher during the Omicron than the Delta surge [40]. However, our study found that the Ct value was not significantly different between Omicron and Delta variants.

Although the clinical outcome of Omicron is less severe than Delta, it should be noted that Omicron has higher transmissibility and immune escape from previous COVID-19 infection and vaccination. These findings caused an extraordinary surge of COVID-19 globally and might affect the healthcare systems, including high absolute numbers of hospital admission and

mortality rates [11]. Indeed, public health measures and vaccination are still crucial to control the COVID-19 spreading and decrease morbidity and mortality.

Several limitations are noted in our study including design of retrospective study, incomplete data on vaccination and previous infection of COVID-19, data were based on hospital admission, but no data from ICU admission unit and the use of mechanical ventilation, no follow-up data for patients after discharge from hospital, and incomparable sample size between Delta and Omicron variants.

Conclusions

Our study shows that patients infected with Omicron and Delta variants reveal similar outcomes, including hospitalization and mortality. In addition, our findings further confirm that older age, cardiovascular disease, and diabetes are the strong prognostic factors for the outcomes of patients with COVID-19.

Data Availability Statement

All data generated or analyzed during this study are included in the submission. The sequence and metadata are shared through GISAID (www.gisaid.org).

Ethics Statement

This study was approved by the Medical and Health Research Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia (KE/FK/0563/EC/2020). The research has been performed following the

Declaration of Helsinki. All participants or guardians signed written informed consent for participating in this study.

Author Contributions

G and KI conceived the study. G drafted the manuscript, and MSH, HW, EA, and TW critically revised the manuscript for important intellectual content. KAV, DAP, GCG, ETG, LSE, FDTU, EMD, LA, NCPK, and VCA performed the library preparation and NGS. G, MSH, ES, IT, KI, REK, A, S, YP, I, SHI, EWD, DAAN, YH, NRA, and TN collected the data; and G, HW, KAV, and DAP analyzed the data. All authors have read and approved the manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of Interests

The authors declared no potential conflicts of interest concerning this article's research, authorship, and/or publication.

Acknowledgments

We thank the Collaborator Members of the Yogyakarta-Central Java COVID-19 study group: Eko Budiono, Heni Retnowulan, Sumardi, Bambang Sigit Riyanto, Munawar Gani, Satria Maulana, Ira Puspitawati, Osman Sianipar (Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/RSUP Dr. Sardjito), Lestari and Herdiyanto Mulyawan (Disease Investigation Center Wates/Balai Besar Besar Veteriner Wates, Yogyakarta), Indaryati and Havid Setyawan (Balai Besar Teknik Kesehatan Lingkungan dan Pengendalian Penyakit,

Yogyakarta), Sri Fatmawati, Fatin Asfarina dan Sumartiningsih (Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada), Safitriani and Muhammad Taufiq Soekarno (PT. Pandu Biosains). We gratefully acknowledge the authors, the originating and submitting laboratories for their sequence and metadata shared through GISAID. We also thank Besar Besar Veteriner Wates (Disease Investigation Center Wates) and Balai Besar Teknik Kesehatan Lingkungan dan Pengendalian Penyakit Yogyakarta, where the virus samples were sequenced using the NGS Illumina MiSeq instrument. All submitters of data may be contacted directly via www.gisaid.org. The Acknowledgments Table for GISAID is reported as Supplementary Table 1. The Indonesian Ministry of Health and Dr. Sardjito Hospital funded our study. The funders had no role in study design, data collection, and analysis, decision to publish, or manuscript preparation.

References

1. Moustafa AM, Planet PJ. Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. *J Pediatric Infect Dis Soc.* 2021 Aug 9:piab051. doi: 10.1093/jpids/piab051. Epub ahead of print. PMID: 34370041; PMCID: PMC8385893.
2. WHO. (World Health Organization): Coronavirus Disease (COVID-2019) Situation Reports. <https://www.who.int/wmergencies/diseases/novel-coronavirus-2019/situation-reports/>. Retrieved on April 4, 2020.
3. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E et al. Coronavirus Pandemic (COVID-19) [Online Resource]. Our World in Data. Available from: <https://ourworldindata.org/coronavirus>. 2020
4. World Health Organization, Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Statement. 2021.
5. Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature.* 2022;603(7902):679-686.
6. Badan Litbangkes Kementerian Kesehatan RI. Peta Sebaran Sekuens dan Varian Covid-19 di Indonesia. <https://www.litbang.kemkes.go.id/peta-sebaran-sekuens-dan-varian-covid-19> Accessed on October 14, 2021.
7. Karim SSA & Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. *Lancet.* 2021;398:2126–2128.
8. Taylor, L. Covid-19: Omicron drives weekly record high in global infections. *BMJ.* 2022;376:o66.

9. GISAID - Initiative [Online Resource]. Gisaid.org.. Available from: <https://www.gisaid.org>. 2022.
10. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. *Lancet*. 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7. PMID:35305296.
11. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. medRxiv 2022.01.11.22269045; doi: <https://doi.org/10.1101/2022.01.11.22269045>.
12. Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments : A Retrospective Cohort Study [published online ahead of print, 2022 March 15]. *Ann Intern Med*. 2022;M22-0308. doi:10.7326/M22-0308. PMID:35286147.
13. Gunadi, Hakim MS, Wibawa H, et al. Is the Infection of the SARS-CoV-2 Delta Variant Associated With the Outcomes of COVID-19 Patients?. *Front Med (Lausanne)*. 2021;8:780611. Published 2021 December 9. doi:10.3389/fmed.2021.780611. PMID:34957154.
14. Gunadi, Hakim MS, Wibawa H, et al. Association between prognostic factors and the outcomes of patients infected with SARS-CoV-2 harboring multiple spike protein mutations. *Sci Rep*. 2021;11(1):21352. Published 2021 Nov 1. doi:10.1038/s41598-021-00459-4. PMID: 34725366.

15. Beeching NJ, Fletcher TE, Fowler R. BMJ best practice. Coronavirus Disease 2019 (COVID-19). <https://bestpractice.bmj.com/topics/en-us/3000168/prognosis> Accessed on August 16 2021.
16. Cho Y, Cho Y, Choi HJ, Lee H, Lim TH, Kang H, Ko BS, Oh J. The effect of BMI on COVID-19 outcomes among older patients in South Korea: a nationwide retrospective cohort study. *Ann Med*. 2021;53(1):1292-1301.
17. Zhou B, Kojima S, Kawamoto A, Fukushima M. COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. *J Med Virol*. 2021;93(5):2694-2704.
18. Gunadi, Wibawa H, Hakim MS, Marcellus, Trisnawati I, Khair RE, et al. Molecular epidemiology of SARS-CoV-2 isolated from COVID-19 family clusters. *BMC Med Genomics*. 2021;14(1):144. PMID:34074255
19. Gunadi, Wibawa H, Marcellus, Hakim MS, Daniwijaya EW, Rizki LP, et al. Full-length genome characterization and phylogenetic analysis of SARS-CoV-2 virus strains from Yogyakarta and Central Java, Indonesia. *PeerJ*. 2020;8:e10575. PMID:33391880.
20. About UGENE - Unipro UGENE Online User Manual v. 1.30 - WIKI [Internet]. Ugene.net. 2020 [cited 22 December 2020]. Available from: <https://ugene.net/wiki/display/UUOUM30/About+UGENE>.
21. Saitou N. and Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. *Molecular Biology and Evolution*. 1987;4:406-425.
22. Felsenstein J. Confidence limits on phylogenies: An approach using the bootstrap. *Evolution*. 1985;39:783-791.

23. Kimura M. A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. *Journal of Molecular Evolution*. 1980;16:111-120.
24. Xia X. DAMBE7: New and improved tools for data analysis in molecular biology and evolution. *Mol Biol Evol*. 2018;35:1550–1552.
25. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. *Mol Biol Evol*. 2018;35:1547-1549.
26. Marçalo R, Neto S, Pinheiro M, Rodrigues AJ, Sousa N, Santos MAS, Simão P, Valente C, Andrade L, Marques A, Moura GR. Evaluation of the genetic risk for COVID-19 outcomes in COPD and differences among worldwide populations. *PLoS One*. 2022 Feb 23;17(2):e0264009.PMID:35196333.
27. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genome-wide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med*. 2020. PMID:32558485.
28. Chu JY, Kaliwal Y, Koh M, Chen R, Chow CM, Ko DT, et al. COVID-19 and its Cardiac and Neurological Complications among Ontario Visible Minorities. *Can J Neurol Sci*. 2021;1–10. PMID:34162448.
29. Ansah JP, Matchar DB, Shao Wei SL, Low JG, Pourghaderi AR, Siddiqui FJ, Min TLS, Wei-Yan AC, Ong MEH. The effectiveness of public health interventions against COVID-19: Lessons from the Singapore experience. *PLoS One*. 2021;16(3):e0248742.
30. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H. Effective public health measures to mitigate the spread of COVID-19: a systematic review. *BMC Public Health*. 2021;21(1):1015.

31. Chaudhry R, Dranitsaris G, Mubashir T, Bartoszko J, Riazi S. A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. *EClinicalMedicine*. 2020;25:100464.
32. Katadata. [Online Resource]. Available from: <https://katadata.co.id/data-corona>. 2022
33. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. *Mol Biol Evol*. 2018;35:1547-1549.
34. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. *PLoS One*. 2021;16(3):e0248281.
35. Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. *BMC Geriatr*. 2021 May 19;21(1):321. doi: 10.1186/s12877-021-02261-3. PMID:34011269.
36. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health*. 2020;13(12):1833-1839.
37. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med*. 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3. PMID:35132265.
38. Kozlov M. Does Omicron hit kids harder? Scientists are trying to find out. *Nature*. 2022; <https://doi.org/10.1038/d41586-022-00309-x>
39. Marks K, Whitaker M, Agathis N, Anglin O, Milucky J, Patel K et al. Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-

NET, 14 States, March 2020–February 2022. MMWR Morbidity and Mortality Weekly Report. 2022;71(11):429-436. PMID: 35298458

40. Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant. medRxiv 2022.01.13.22269257; doi: <https://doi.org/10.1101/2022.01.13.22269257>

Figure Legend

Figure 1. Phylogenetic analysis of Omicron and Delta variants of SARS-CoV-2 virus collected from Central Java and Yogyakarta regions from 2021-2022.

Phylogenetic trees are displayed in rectangular (a) and polar (b) layouts. The evolutionary history was inferred using the Neighbor-Joining method [1] and computed using the Kimura 2-parameter [2] method with 1000 bootstrap replication in MEGA X [3,4]. The number of base substitutions per site (0.0001) is shown on the left of the rectangular tree, where the rate variation among sites was modeled with a gamma distribution. This analysis involved 392 nucleotide sequences, a total of 29,409 positions in the final dataset. Moreover, all ambiguous positions were removed for each sequence pair (pairwise deletion option). The Delta variant taxa are indicated in red, followed by Omicron-BA.1-like in blue, Omicron-BA.2-like in green, Omicron-BA.3-like in purple, and other variants previously circulating in Indonesia that are involved in this analysis are indicated in black.

